This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

10 Biotech Stocks On the Line

BOSTON ( TheStreet) -- Shares of InterMune (ITMN) are up almost 180% since last Friday. For investors who owned the drug company's stock last week, that means their investment more than doubled in value in just four trading sessions.

Only in biotech can such volatility generate huge windfalls for investors -- those armed with a simple calendar of stock-moving events.

FDA advisory panels (in the case of InterMune), drug approval decision dates and clinical trial results move biotech stocks -- a lot. Keeping close tabs on these stock-moving events is an essential task for every successful biotech investor.

Not all biotech stocks rocket like InterMune. Some crash to earth like Medivation (MDVN), which lost 70% of its value after the failure of pivotal phase III drug study. But even here, investors who knew approximately when the Medivation data were to be released could have booked profits in advance or used options to hedge their investment and cushion the blow from a bad outcome.

Either way, investors caught unaware by the timing of biotech events either miss a moneymaking opportunity or get blindsided by a blowup.

Here are ten biotech and drug companies with stock-moving events in the next few months. Some of these stocks might be the next InterMune; others might end up more like Medivation. Either way, it pays to keep a biotech events calendar handy.

1 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CTIC $1.80 -6.00%
AFFY $0.11 -5.61%
DCTH $1.05 0.00%
DNDN $0.06 -6.02%
MNKD $5.10 0.10%

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs